Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)

The summary for the Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required): This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts. This NOFO uses a cooperative agreement mechanism (U01) and runs in parallel with a companion NOFO (RFA-DK-27-136).

Federal Grant Title:	Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-27-121
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 9th, 2026
Original Application Deadline:	October 9th, 2026
Posted Date:	June 8th, 2026
Creation Date:	June 8th, 2026
Archive Date:	December 8th, 2026
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:	$1,000,000
Minimum Federal Grant Award:
Expected Number of Awards:	3
Cost Sharing or Matching:	No
Last Updated:	June 8th, 2026

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Grant Announcement Contact: Office of Obesity Research
[email protected]
[email protected]
Similar Government Grants: • Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional); • Silvio O. Conte Digestive Diseases Research Core Centers (P30-Clinical Trial Optional); • Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Ad...; • Kidney Precision Medicine Project Central Hub (U24 Clinical Trial Not Allowed); • Kidney Precision Medicine Project Tissue Interrogation Sites (U01 Clinical Trial Not Allow...; • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial...; • Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VC...; • Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional); • Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal ...; • PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine...